First-line Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors for EGFR Mutant Non-small Cell Lung Cancer: And the Winner is...

被引：3
|
作者：
Juan, O. [1 ,2 ]
Yousaf, N. [2 ]
Popat, S. [2 ,3 ,4 ]
机构：
[1] Univ Hosp La Fe, Dept Med Oncol, Valencia, Spain
[2] Royal Marsden Hosp, Lung Unit, London, England
[3] Imperial Coll London, Fac Med, Natl Heart & Lung Inst, London, England
[4] Inst Canc Res, London, England
来源：
CLINICAL ONCOLOGY | 2017年 / 29卷 / 01期
关键词：
OPEN-LABEL; PHASE-III; PROGRESSION-FREE; CHEMOTHERAPY; ERLOTINIB; AFATINIB; ADENOCARCINOMA; MUTATIONS; GEFITINIB; SURVIVAL;
D O I：
10.1016/j.clon.2016.09.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E1 / E4
页数：4
相关论文
共 50 条
  • [11] Tyrosine Kinase Inhibitors and Epidermal Growth Factor Receptor (EGFR) Mutations in Non-Small Cell Lung Cancer To Test or Not to Test?
    Gazdar, Adi F.
    MEDICINE, 2011, 90 (03) : 168 - 170
  • [12] Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors on Brain Metastases in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
    Zhou, Qing
    Zhang, Xuchao
    Xu, Chongrui
    Yang, Jinji
    Yang, Xuening
    An, Shejuan
    Chen, Zhihong
    Su, Jian
    Wang, Binchao
    Huang, Yisheng
    Wang, Zhen
    Huang, Yujuan
    Wu, Yi-Long
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S398 - S398
  • [13] PHARMACOECONOMIC ASPECTS OF DIFFERENT INHIBITORS OF TYROSINE KINASE IN FIRST-LINE THERAPY OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WITH A MUTATION IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) GENE
    Ryazhenov, V. V.
    Gorokhova, S. G.
    Gorokhov, V
    VALUE IN HEALTH, 2016, 19 (07) : A720 - A720
  • [14] First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer
    Greenhalgh, Janette
    Dwan, Kerry
    Boland, Angela
    Bates, Victoria
    Vecchio, Fabio
    Dundar, Yenal
    Jain, Pooja
    Green, John A.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (05):
  • [15] First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer
    Greenhalgh, Janette
    Boland, Angela
    Bates, Victoria
    Vecchio, Fabio
    Dundar, Yenal
    Chaplin, Marty
    Green, John A.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (03):
  • [16] First-Line Treatment in eGFR Mutant non-Small Cell Lung Cancer: is There a Best Option?
    Bulbul, Ajaz
    Husain, Hatim
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [17] Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs)
    Mountzios, Giannis
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (08)
  • [18] Impact of Weight Loss at Presentation on Survival in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) Sensitive Mutant Advanced Non-small Cell Lung Cancer (NSCLC) Treated with First-line EGFR-TKI
    Lin, Liping
    Zhao, Juanjuan
    Hu, Jiazhu
    Huang, Fuxi
    Han, Jianjun
    He, Yan
    Cao, Xiaolong
    JOURNAL OF CANCER, 2018, 9 (03): : 528 - 534
  • [19] Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations
    Suh, Koung Jin
    Keam, Bhumsuk
    Kim, Miso
    Park, Young Sik
    Kim, Tae Min
    Jeon, Yoon Kyung
    Kim, Dong-Wan
    Chung, Doo Hyun
    Kim, Young Whan
    Heo, Dae Seog
    CLINICAL LUNG CANCER, 2016, 17 (04) : 245 - +
  • [20] Upfront versus Delayed Stereotactic Radiosurgery for Brain Metastases in Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors
    Dohm, Ammoren
    Tang, Joseph
    Mills, Matthew
    Perez, Bradford
    Robinson, Timothy
    Creelan, Ben
    Gray, Jhanelle
    Etame, Arnold
    Vogelbaum, Michael
    Forsyth, Peter
    Yu, Hsiang-Hsuan Michael
    Oliver, Daniel
    Ahmed, Kamran
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021, 44 (10): : S112 - S113
12345